Share

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Recent Publications

Impact of the American Society of Breast Surgeons' Guidelines on Genetic Testing and Contralateral Prophylactic Mastectomy Rates

Published On 2025 Mar 20

Journal article

CONCLUSIONS: Despite increasing GT rates, CPM rates were stable over time and were not associated with GT, indicating that offering GT to more patients does not necessarily increase CPM rates.


Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes

Published On 2025 Jan 02

Journal article

CONCLUSIONS AND RELEVANCE: In this cohort study, individuals with 2 LR variants in CHEK2 had a cancer phenotype similar to those with a single LR variant and similar to WT controls. Individuals with 1 PV and 1 LR variant may have a more penetrant cancer phenotype than individuals with a single PV. Future studies focused on CHEK2 LR variants will aid in better understanding whether these variants are genetic modifiers associated with cancer risk.